Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Charcot-Marie-Tooth disease type 4B1 (CMT4B1) is a subtype of Charcot-Marie-Tooth disease type 4 characterized by an early childhood-onset of severe, demyelinating sensorimotor neuropathy, various degrees of complex myelin outfoldings seen on peripheral nerve biopsy, very slow, and often undetectable, nerve conduction velocities, and the typical CMT phenotype (i.e. distal muscle weakness and atrophy, sensory loss, and frequent pes cavus). Other reported features include facial weakness, vocal cord paresis, respiratory difficulties, and skeletal deformities (e.g. chest deformities, claw hands, pes equinovarus).
Features include always present findings: Distal amyotrophy. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 2 | Distal muscle weakness, Proximal muscle weakness |
Head and neck | 1 | Facial palsy |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
MTMR2 encodes myotubularin related protein 2 (643 aa). Lipid phosphatase that specifically dephosphorylates the D-3 position of phosphatidylinositol 3-phosphate and phosphatidylinositol 3,5-bisphosphate, generating phosphatidylinositol and phosphatidylinositol 5-phosphate. Highest expression in Artery Tibial (27.3 TPM) and Artery Aorta (26.0 TPM).
Charcot-Marie-Tooth disease type 4B1 is associated with mutations in the MTMR2 gene on chromosome 11.
MTMR2 is classified as a druggable target (Druggable Genome, Enzyme, Myotubularin Related Protein Phosphatase, and Protein Phosphatase categories) with score 0.0.
Genetic testing for MTMR2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 4B1. Research spans Epidemiology / Natural History (67%) and Basic Science / Preclinical (33%).
Bertini A (2025). [PMID: 39943887](https://pubmed.ncbi.nlm.nih.gov/39943887/). *European journal of neurology*. [Epidemiology / Natural History]
Alsehli H (2024). [PMID: 38600369](https://pubmed.ncbi.nlm.nih.gov/38600369/). *Scientific reports*. [Epidemiology / Natural History]
Du N (2024). [PMID: 38835974](https://pubmed.ncbi.nlm.nih.gov/38835974/). *The application of clinical genetics*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 4B1